Organogenesis Holdings Inc. develops, manufactures and sells regenerative medicine and tissue-innovation products for the Advanced Wound Care and Surgical & Sports Medicine markets. News about the company commonly covers product revenue by those markets, gross margin and profitability trends, and corporate updates tied to its Nasdaq-listed Class A common stock.
Company updates also focus on clinical and regulatory activity across its portfolio. Recurring subjects include PuraPly AM clinical evidence in diabetic foot ulcers, ReNu as a cryopreserved amniotic suspension allograft for symptomatic knee osteoarthritis, FDA interactions, Biologics License Application activity, and coverage or payment developments affecting skin-substitute and wound-care products.
Organogenesis Holdings (Nasdaq: ORGO) reported third-quarter 2026 net product revenue of $45.5 million, down sharply from the prior year. Revenue fell 70% from $150.5 million, with Advanced Wound Care down 73% and Surgical & Sports Medicine down 19%. Gross margin fell to 52% from 76%. Net loss was $29.6 million, versus net income of $21.6 million; diluted earnings per share moved to a $0.25 loss from $0.11 income.
Nine-month net product revenue fell 63% to $124.5 million, and net loss widened to $179.1 million from $6.7 million. September 30 cash and cash equivalents were $21.326 million, versus $93.679 million at December 31, 2025. The company now expects 2026 revenue of $179.4 million–$200.0 million, down 65%–68% from 2025, with fourth-quarter sequential improvement at a more measured rate than previously assumed.
Organogenesis (ORGO) announced publication of previously released PREPARE trial results showing improved wound closure with PuraPly AM in hard-to-heal diabetic foot ulcers.
The results appeared in the Journal of Wound Care. PREPARE was a prospective, multicenter, randomized controlled trial, following patients across multiple sites and comparing randomly assigned treatments. It evaluated PuraPly AM plus standard of care against standard of care alone. The trial achieved its primary endpoint and showed statistically significant improvements in wound closure at 12 weeks among patients receiving the combination.
Organogenesis expects the evidence to form the basis for future coverage decisions for PuraPly AM; those decisions were not announced as completed.
Organogenesis Holdings (Nasdaq: ORGO) will report its third-quarter fiscal 2026 financial results after market close on November 5, 2026.
Management will host a conference call at 5:00 p.m. Eastern Time that day to discuss quarterly results, provide a corporate update and hold a question-and-answer session. The webcast will be available on the investor website and archived for approximately one year.
Organogenesis (Nasdaq: ORGO) reported second quarter 2026 net product revenue of $42.8 million, down 58% from $100.8 million in 2025, driven by a 61% decline in Advanced Wound Care revenue to $36.1 million and an 18% decline in Surgical & Sports Medicine to $6.7 million.
Gross profit fell to $19.1 million (45% margin) from $73.1 million (73% margin). Net loss widened to $96.3 million or $(0.77) per share, with adjusted EBITDA loss of $34.4 million. For the first half of 2026, net product revenue was $79.1 million, down 58% year over year, and net loss was $149.4 million.
As of June 30, 2026, Organogenesis held $46.8 million in cash, cash equivalents and restricted cash and had no outstanding debt. For full year 2026, the company now expects total net revenue of $179.0–$215.0 million, implying a 62–68% decline versus 2025 and a deeper second-half decline than prior guidance.
Organogenesis (Nasdaq: ORGO) reported peer-reviewed results from a 206-patient, prospective, multicenter randomized controlled trial evaluating Affinity plus standard of care (SoC) versus SoC alone in complex venous leg ulcers (VLUs). Results published in the Journal of Wound Care showed statistically significant improvements (p<0.05) in wound closure at weeks 12 and 16 for the Affinity + SoC arm across two baseline wound duration strata: wounds present >6 months and >24 months.
The trial included a four-week run-in and 24-week follow-up. According to Organogenesis, these data strengthen the evidence base for Affinity as a protective barrier in some of the hardest-to-heal chronic wounds and complement existing randomized and real‑world data in diabetic foot ulcers, supporting the clinical and economic rationale for broader coverage in VLUs and DFUs.
Organogenesis (Nasdaq: ORGO) will report second quarter fiscal 2026 financial results after market close on Thursday, August 6, 2026. Management will host a 5:00 p.m. ET conference call and live webcast, including a corporate update and Q&A session.
The webcast will be available at investors.organogenesis.com and archived for about one year.
Organogenesis (Nasdaq: ORGO) announced FDA acceptance for review of its Biologics License Application (BLA) for ReNu, a cryopreserved amniotic suspension allograft for managing pain in symptomatic knee osteoarthritis.
The FDA set a PDUFA target action date of April 24, 2027. Knee osteoarthritis affects nearly 31 million Americans and is projected to exceed 34 million by 2027.
Organogenesis (Nasdaq: ORGO) reported Q1 2026 results for the quarter ended March 31, 2026. Net product revenue was $36.3M, down $50.4M (58%) from Q1 2025; Advanced Wound Care revenue fell to $29.5M (down 63%). Net loss was $53.2M, or $(0.44) per share. Cash and restricted cash totaled $92.1M; no outstanding debt. The company narrowed FY2026 revenue guidance to $270.0M–$310.0M, reflecting an assumed sequential recovery in H2 2026.
Organogenesis (Nasdaq: ORGO) completed a rolling Biologics License Application (BLA) submission to the FDA for ReNu, a cryopreserved amniotic suspension allograft for symptomatic knee osteoarthritis (OA).
The company began rolling submission in December 2025 and finished with clinical and CMC modules on April 28, 2026. Knee OA affects an estimated 31.1 million Americans, projected to reach 34.4 million by 2027.
Organogenesis (Nasdaq: ORGO) reported that a prospective, multi-center randomized controlled trial of 170 patients showed PuraPly AM plus standard of care achieved the primary endpoint of statistically significant diabetic foot ulcer (DFU) wound closure at 12 weeks (p < 0.0477).
Organogenesis said the trial evaluated safety and efficacy, plans peer-reviewed publication, and believes results will support future coverage decisions for PuraPly AM.